Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
49,537 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Experimental and Computational Approaches to Identify Noncoding Pathogenic Variation in Rare Disease.
Covill LE, Romo L, O'Donnell-Luria A. · Annu Rev Genomics Hum Genet · 2026 · cited 0 timessystematic review
- Current state and demographic trends of medically underserved populations in rare disease research in the United States: a systematic review.
Manjunatha L, Ms S, Dokuru D, Venugopal N, Waldrop JN, Blount LG, Kartha RV, Rajasimha HK. · BMC Health Serv Res · 2026 · cited 0 timessystematic review
- Best practices in demographic data collection for equity, diversity, and inclusion in rare disease research: A systematic review.
Sinan I, Johnston M, Marwaha A. · Genet Med · 2026 · cited 0 timesresearch support, non-u.s. gov't, systematic review
- Comparing the performance of exome and genome sequencing for rare disease diagnostics: A randomized implementation effectiveness trial.
Hayeems RZ, Ungar WJ, Marshall CR, Gillespie MK, Szuto A, Huang L, Venkataramanan V, Xiao B, Chisholm C, Stavropoulos DJ, Bergeron MB, Lee W, Costain G, Jobling R, Sawyer S, Price EM, Lau L, Mendoza R, Somerville MJ, Boycott KM. · Genet Med · 2026 · cited 4 timesresearch support, non-u.s. gov't, randomized controlled trial
- Quantifying hope: an EU perspective of rare disease therapeutic space and market dynamics.
Cacoub E, Lefebvre NB, Milunov D, Sarkar M, Saha S. · Front Public Health · 2025 · cited 5 timesOpen accesssystematic review, systematic-review
- Global insight into rare disease and orphan drug definitions: a systematic literature review.
Abozaid GM, Kerr K, Alomary H, Al-Omar HA, McKnight A. · BMJ Open · 2025 · cited 11 timesOpen accesssystematic review
- Capturing Real-World Rare Disease Patient Journeys: Are Current Methodologies Sufficient for Informed Healthcare Decisions?
Cribbs KA, Blackmore LTA, Banks AR, Kim DS, Lahue BJ. · J Eval Clin Pract · 2025 · cited 1 timesOpen accesssystematic review, review-article
- Assessing Psychological Harms on Parents and Primary Caregivers of Children Living with a Rare Disease: A Systematic Review of the Scope and Validity of Surveys Utilized.
Bull LJ, Eslick GD, Teutsch SM, Elliott EJ. · Clin Child Fam Psychol Rev · 2025 · cited 0 timesOpen accessresearch support, non-u.s. gov't, systematic review
- TRIAGE-GS: protocol for a randomised controlled trial of a genomics-first approach to rare disease diagnosis for patients awaiting assessment by a clinical geneticist.
Stanley KJ, Chisholm C, Gillespie MK, Caluseriu O, Del Signore N, Elango S, Hartley T, Hewson S, Kim RH, McSheffrey G, Mendoza-Londono R, Sawyer SL, Somerville M, Venkataramanan V, White-Brown A, Telesca S, Shickh S, Marshall CR, Ungar WJ, Hayeems RZ, Bhawra J, Boycott KM, Costain G. · BMJ Open · 2025 · cited 0 timesOpen accessclinical trial protocol
- Assessing the effectiveness of measurement scales in evaluating the health-related quality of life in rare disease patients after treatment: a systematic review.
Dumbuya JS, Ahmad B, Zeng C, Chen X, Lu J. · Health Qual Life Outcomes · 2024 · cited 9 timesOpen accesssystematic review
- Improving the care of children with GENetic Rare disease: Observational Cohort study (GenROC)-a study protocol.
Low KJ, Watford A, Blair P, Nabney I, Powell J, Wynn SL, Foreman J, Firth H, Ingram J. · BMJ Open · 2024 · cited 10 timesOpen accessclinical trial protocol, research support, non-u.s. gov't
- Challenges in multinational rare disease clinical studies during COVID-19: regulatory assessment of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease.
Schoser B, Attarian S, Graham R, Holdbrook F, Goldman M, Díaz-Manera J, ATB200-03 study group. · J Neurol · 2025 · cited 2 timesOpen accessclinical trial, phase iii, multicenter study
- Evaluation of the Health-Related Quality of Life and Mental Health of Parents With Children and Adolescents With a Rare Disease Based on the Results of a Randomized Controlled Trial to Investigate a Family-Based Intervention and an Online Intervention for Affected Families (CARE-FAM-NET).
Steinberg A, Boettcher J, Leidger A, Muntau AC, Denecke J, Kaiser N, Daubmann A, Zapf A, Wegscheider K, Ozga AK, Suling AI, Bullinger M, Quitmann J, Dirmaier J, Witt S, Rezvani F, Mundlos C, Biehl L, Rassenhofer M, Fegert JM, Tutus D, Willms G, Zeidler J, Pardey N, von der Schulenburg JG, Wiegand-Grefe S. · Fam Process · 2025 · cited 1 timesOpen accessmulticenter study, randomized controlled trial
- Systematic review on groove pancreatitis: management of a rare disease.
Ukegjini K, Steffen T, Tarantino I, Jonas JP, Rössler F, Petrowsky H, Gubler C, Müller PC, Oberkofler CE. · BJS Open · 2023 · cited 19 timesOpen accesssystematic review, review-article
- Prioritization of research engaged with rare disease stakeholders: a systematic review and thematic analysis.
Yoon S, Lee M, Jung HI, Khan MM, Kim SY, Kim H, Wasti S. · Orphanet J Rare Dis · 2023 · cited 6 timesOpen accessresearch support, non-u.s. gov't, systematic review
- The management of rare disease patients from a grassroot perspective: the role of patients' organizations in the global recognition of rare diseases in Cameroon.
Ngoumou RD, Feudjio YBD. · Pan Afr Med J · 2024 · cited 2 timesOpen accesssystematic review
- Inflammatory Bowel Disease and Interleukin-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis.
Cutrona M, Jolkovsky EL, Romanelli S, O'Hagan R, Cices A. · JAMA Dermatol · 2026 · cited 0 timesmeta-analysis, systematic review
- Subcutaneous infliximab for maintenance therapy in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis.
Miotto DADSM, Ramos IO, Grassi CM. · Eur J Pediatr · 2026 · cited 0 timesmeta-analysis, systematic review
- The Korean Genetic Diagnosis Program for Rare Disease Phase II: outcomes of a 6-year national project.
Kim MJ, Kim B, Lee H, Lee JS, Chae SW, Shin HS, Cho SI, Kim SY, Moon J, Lim BC, Ko JM, Chae JH, Park SS, Seong MW. · Eur J Hum Genet · 2023 · cited 6 timesclinical trial, phase ii, research support, non-u.s. gov't
- Switching from Intravenous to Subcutaneous Infliximab in Children with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Spencer EA. · Curr Gastroenterol Rep · 2026 · cited 0 timesmeta-analysis, systematic review
- Dupilumab-associated eosinophilia in chronic rhinosinusitis with nasal polyps: frequency, temporal dynamics, predictors, and clinical consequences-a systematic review and meta-analysis.
Torretta S, Cavaleri L, Cozzi A, Cavalera SM, Battilocchi L. · Front Immunol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Efficacy and safety of tolebrutinib in multiple sclerosis: a systematic review and meta-analysis.
Mosad N, Roshdy Y, Emad T, Harb A, Abo-Elnour DE, Awadalla YF, Al Fauomi W, Alnajjar AZ. · Neurol Sci · 2026 · cited 0 timesmeta-analysis, systematic review
- Efficacy of Tecovirimat for the Treatment of Mpox Virus Infection in Humans: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Grecco DM, Araldi L, Soldera GC, Zimmermann JAB, Brisolara JV, Artero GA, Streher LF, Turatti MEF, Harapan H. · Rev Med Virol · 2026 · cited 0 timesmeta-analysis, systematic review
- Fertility Treatment and Risk of Melanoma: A Certainty-Rated Systematic Review and Meta-Analysis of 3,733,499 Women.
Stylianakis D, Solinas C, Petrelli F, Nazzaro G, Passoni E, Martella S, Stylianakis I, Atzori L, Scartozzi M, Lambertini M, Garrone O, Denaro N. · Eur J Clin Invest · 2026 · cited 0 timesmeta-analysis, systematic review
- Biologic Therapy in Pityriasis Rubra Pilaris: Systematic Review and Meta-analysis with Class-based Comparisons.
Tartaglia J, Moscardi A, Garbo C, Celin G, Mazzetto R, Piaserico S. · Acta Derm Venereol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.